1

Exelixis

#2129

Rank

$7.6B

Marketcap

US United States

Country

Exelixis
Leadership team

Dr. Stelios Papadopoulos Ph.D. (Co-Founder & Independent Chair of the Board)

Dr. Michael M. Morrissey Ph.D. (CEO, Pres & Director)

Mr. Christopher J. Senner (Exec. VP & CFO)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
500 - 1000
Headquarters
Alameda, California, United States
Established
1994
Company Registration
SEC CIK number: 0000939767
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
EXEL
Social Media
Overview
Location
Summary
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
History

Exelixis was founded in 1995 and went public in 2000. The company remains focused exclusively on cancer research, pioneering many new approaches to treating the disease and to developing targeted therapies. Over its history, Exelixis has obtained a number of breakthrough successes, including the discovery of its product portfolio, which includes medicines that are now being used to treat advanced cancers.

Key Team

Dr. Peter Lamb Ph.D. (Exec. VP of Scientific Strategy & Chief Scientific Officer)

Mr. Jeffrey J. Hessekiel J.D. (Exec. VP, Gen. Counsel & Sec.)

Mr. Patrick J. Haley M.B.A., MBA (Exec. VP of Commercial)

Dr. Dana T. Aftab Ph.D. (Exec. VP of Bus. Operations)

Ms. Susan T. Hubbard (Exec. VP of Public Affairs & Investor Relations)

Mr. Gregg Bernier (VP of Marketing)

Ms. Laura Dillard (Exec. VP of HR)

References
Exelixis
Leadership team

Dr. Stelios Papadopoulos Ph.D. (Co-Founder & Independent Chair of the Board)

Dr. Michael M. Morrissey Ph.D. (CEO, Pres & Director)

Mr. Christopher J. Senner (Exec. VP & CFO)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
500 - 1000
Headquarters
Alameda, California, United States
Established
1994
Company Registration
SEC CIK number: 0000939767
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
EXEL
Social Media